Company Name: Biocept (Nasdaq:)
Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic
President & CEO
Mr. Nall has over 30 years of healthcare leadership experience and has been our President and CEO since 2013. During this time, the company has transitioned from R and D to Commercialization. Mr. Nall has previously served in Commercial and Operational leadership roles in multiple companies including his most recent role as General Manager, North America Sales and Marketing for GE Healthcare’s Clarient division, leading all aspects of commercialization including Sales, Marketing and Reimbursement for Laboratory Services. Prior to Clarient, Mr. Nall served at Impath, Maquet Surgical, Midwest Medical, CVS Specialty Distribution and American Cyanamid.
Mr. Nall also serves on a non-profit board for the Clearity Foundation which is dedicated to providing support for women diagnosed with Ovarian Cancer.